EMBARK vs Psilocybin-Assisted Therapy
A side-by-side comparison of recorded mechanisms, evidence review status, related condition topics, and philosophical roots.
At a glance
Source checks, condition-specific assessments and expert review are separate steps. Each assessment applies only to its stated population and use. Topic links do not establish comparative effectiveness.
EMBARK
- Tradition
- Psychedelic
- Founder
- Brennan / Belser (2022)
- Review status
- Assessment not yet completed
- Focus
- Integration + Processing
- Format
- Individual (dyadic facilitation team)
- Duration
- Variable (structured phases: preparation, medicine sessions, integration)
Psilocybin-Assisted Therapy
- Tradition
- Psychedelic
- Founder
- Griffiths / Carhart-Harris (2016)
- Review status
- 1 condition assessment available
- Official sources
Guidelines and official sources (3)
2 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- FDA accelerates action on treatments for serious mental illness following Executive Order
Not a treatment recommendation
FDA announced priority vouchers for psilocybin studies in April 2026. This establishes development activity, not approval or psychotherapy endorsement.
Scope: Companies studying psilocybin for TRD and MDD
- Management of Major Depressive Disorder
Recommendation against the stated use
VA/DoD strongly recommends against psilocybin for MDD outside research. This 2022 guideline used evidence through January 2021 and does not review subsequent trials.
Scope: Psilocybin for MDD outside research settings
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD finds insufficient evidence for or against psilocybin for PTSD. The statement does not separately establish a psychotherapy-protocol recommendation.
Scope: Psilocybin pharmacotherapy for adult PTSD; evidence reviewed through May 2022.
- FDA accelerates action on treatments for serious mental illness following Executive Order
- Focus
- Experiential + Processing
- Format
- Individual
- Duration
- Short (1-3 doses)
Condition-specific assessments
Each conclusion applies to the population and use described. These source-based assessments do not certify the full entry or replace expert clinical review.
Existential & Meaning-Making Concerns
Population and scope: Carefully selected adults with a potentially life-threatening cancer diagnosis and anxiety/mood symptoms, receiving psilocybin with substantial preparation, monitored sessions and follow-up support.
Randomized studies
Griffiths et al. (2016) randomized dose order in a crossover study: 56 people were assigned and 51 completed at least one session. Higher-dose treatment favored several mood and existential outcomes compared with the very-low-dose condition, including life meaning and death acceptance. After crossover at five weeks, the six-month observations lacked an unexposed comparison. The small, predominantly White, highly educated sample, expectancy and masking limits, and intensive support restrict generalization. Transient anxiety, psychological distress and blood-pressure increases occurred. This is a trial-design assessment for that supervised research context, not a guideline endorsement or evidence for all meaning-making concerns or unsupervised use.
Source assessment dated
How they work
EMBARK
Core mechanism: Six domains the model holds to be common in psychedelic states organize preparation and integration; four 'care cornerstones' are meant to keep delivery ethical, trauma-informed, and culturally responsive. The structure organizes the therapy rather than explaining how psychedelics work.
Ontology: A whole person whose psychedelic experience activates multiple dimensions simultaneously (existential, somatic, relational, affective-cognitive) requiring a multi-domain therapeutic response rather than a single-mechanism model
Psilocybin-Assisted Therapy
Core mechanism: Psilocybin disrupts default mode network activity; on the standard account the mystical-type experience this can occasion is what produces lasting shifts in perspective and meaning, though whether that experience is necessary to the effect is actively disputed
Ontology: Rigid self-referential processing (depression) or compulsive patterns maintained by entrenched neural networks
Related condition topics
These editorial cross-references organize reading. A shared link does not mean both approaches are effective, recommended, or interchangeable for that condition.
3 shared · 3 EMBARK-only · 0 Psilocybin-Assisted Therapy-only
Linked to both entries
Linked only in the EMBARK entry
What each assumes — and misses
EMBARK
Philosophical roots: Grof (non-ordinary states); James (varieties of religious experience); harm reduction philosophy; CBT, ACT, and psychodynamic traditions integrated
Blind spots: Developed within a pharmaceutical research context (Cybin); limited independent replication; open-source status means variable implementation quality; requires specialized training not yet standardized across programs
Therapeutic voice: You keep coming back to what your body was doing when it started. Let's stay there a while before we go to what it meant.
Psilocybin-Assisted Therapy
Philosophical roots: James (mystical experience); Huxley (doors of perception, reducing valve theory); Watts (ego dissolution); Buddhist concepts (non-self, interconnection); Carhart-Harris (entropic brain hypothesis)
Blind spots: Not FDA approved; challenging experiences can be destabilizing; standardization of therapy component still developing
Therapeutic voice: Whatever comes, let it come. Whatever goes, let it go. Trust the process.
Choosing between them
EMBARK and Psilocybin-Assisted Therapy both sit within the Psychedelic tradition — they share a worldview about what suffering is and how change happens. Differences are more often about technique and emphasis than about underlying theory.
For deeper coverage: see the full EMBARK and Psilocybin-Assisted Therapy pages, or use the interactive comparison tool to add more modalities to this comparison.